| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
47,962,000 |
| Market
Cap: |
24.08(M) |
| Last
Volume: |
12,631,282 |
Avg
Vol: |
9,816,483 |
| 52
Week Range: |
$0.502 - $0.8399 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Co. markets Inbrija (levodopa inhalation powder), which is approved for intermittent treatment of episodic motor fluctuations, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija utilizes Co.'s ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. Co. also markets Ampyra (dalfampridine) extended release tablets, 10 mg for improving walking in patients with multiple sclerosis. Ampyra is marketed as Fampyra outside the U.S.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
20,156 |
| Total Buy Value |
$0 |
$0 |
$0 |
$12,594 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cohen Ron |
President and CEO |
• – – |
2008-07-08 |
4 |
OE |
$2.60 |
$65,000 |
D/D |
25,000 |
182,384 |
|
- |
|
| Phillips Barclay A |
Director |
– • – |
2008-06-13 |
4 |
S |
$30.20 |
$7,120,079 |
I/I |
(235,000) |
308,801 |
|
- |
|
| Lawrence David |
Chief Financial Officer |
• – – |
2008-06-12 |
4 |
S |
$21.67 |
$218,622 |
D/D |
(7,000) |
12,400 |
|
- |
|
| Lawrence David |
Chief Financial Officer |
• – – |
2008-06-12 |
4 |
OE |
$5.85 |
$40,950 |
D/D |
7,000 |
19,400 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-12 |
4 |
S |
$30.52 |
$282,037 |
D/D |
(9,200) |
49,315 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-12 |
4 |
OE |
$2.60 |
$75,920 |
D/D |
29,200 |
58,515 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-12 |
4 |
S |
$31.70 |
$57,087 |
D/D |
(1,800) |
29,315 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-12 |
4 |
S |
$31.26 |
$277,239 |
D/D |
(8,800) |
31,115 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-12 |
4 |
S |
$30.82 |
$275,218 |
D/D |
(8,900) |
39,915 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-11 |
4 |
S |
$31.50 |
$25,220 |
D/D |
(800) |
29,315 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-11 |
4 |
OE |
$2.60 |
$2,080 |
D/D |
800 |
30,115 |
|
- |
|
| Wasman Jane |
Exec VP, General Counsel & Sec |
• – – |
2008-06-11 |
4 |
S |
$31.50 |
$110,420 |
D/D |
(3,500) |
26,164 |
|
- |
|
| Wasman Jane |
Exec VP, General Counsel & Sec |
• – – |
2008-06-11 |
4 |
OE |
$5.85 |
$20,475 |
D/D |
3,500 |
29,664 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-05 |
4 |
AS |
$29.84 |
$112,327 |
D/D |
(3,700) |
29,315 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-05 |
4 |
AS |
$31.17 |
$127,270 |
D/D |
(4,000) |
33,015 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-05 |
4 |
AS |
$32.04 |
$225,761 |
D/D |
(7,000) |
37,015 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-05 |
4 |
AS |
$32.38 |
$172,543 |
D/D |
(5,300) |
44,015 |
|
- |
|
| Blight Andrew |
Chief Scientific Officer |
• – – |
2008-06-05 |
4 |
OE |
$2.60 |
$52,000 |
D/D |
20,000 |
49,315 |
|
- |
|
| Cohen Ron |
President and CEO |
• – – |
2008-06-05 |
4 |
S |
$32.01 |
$314,271 |
D/D |
(9,800) |
157,384 |
|
- |
|
| Cohen Ron |
President and CEO |
• – – |
2008-06-05 |
4 |
S |
$31.50 |
$1,268,922 |
D/D |
(40,200) |
167,184 |
|
- |
|
| Cohen Ron |
President and CEO |
• – – |
2008-06-05 |
4 |
OE |
$2.60 |
$130,000 |
D/D |
50,000 |
207,384 |
|
- |
|
| Lawrence David |
Chief Financial Officer |
• – – |
2008-06-04 |
4 |
S |
$29.76 |
$357,873 |
D/D |
(12,000) |
12,400 |
|
- |
|
| Lawrence David |
Chief Financial Officer |
• – – |
2008-06-04 |
4 |
S |
$29.39 |
$623,425 |
D/D |
(21,106) |
24,400 |
|
- |
|
| Lawrence David |
Chief Financial Officer |
• – – |
2008-06-04 |
4 |
OE |
$2.60 |
$168,954 |
D/D |
30,890 |
45,506 |
|
- |
|
| Wasman Jane |
Exec VP, General Counsel & Sec |
• – – |
2008-05-12 |
4 |
AS |
$19.00 |
$46,341 |
D/D |
(2,425) |
26,164 |
|
- |
|
610 Records found
|
|
Page 19 of 25 |
|
|
